Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.2854
+0.0105 (3.82%)
At close: Aug 7, 2026, 4:00 PM EDT
0.2770
-0.0084 (-2.94%)
After-hours: Aug 7, 2026, 7:45 PM EDT
Valion Bio Employees
Valion Bio had 52 employees as of December 31, 2025. The number of employees increased by 45 or 642.86% compared to the previous year.
Employees
52
Change (1Y)
45
Growth (1Y)
642.86%
Revenue / Employee
n/a
Profits / Employee
-$265,635
Market Cap
913.52K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 52 | 45 | 642.86% |
| Dec 31, 2024 | 7 | -2 | -22.22% |
| Dec 31, 2023 | 9 | -7 | -43.75% |
| Jun 30, 2023 | 11 | - | - |
| Dec 31, 2022 | 16 | 9 | 128.57% |
| Dec 31, 2021 | 7 | -1 | -12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 47 |
| Scinai Immunotherapeutics | 45 |
| Calidi Biotherapeutics | 29 |
| VivoSim Labs | 15 |
| Silexion Therapeutics | 14 |
| Genprex | 13 |
| Biodexa Pharmaceuticals | 11 |
| Decoy Therapeutics | 11 |
VBIO News
- 16 days ago - Valion Bio’s regulatory dossier for Entolimod accepted for review in Ukraine - TheFly
- 16 days ago - Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway - PRNewsWire
- 18 days ago - World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market - PRNewsWire
- 21 days ago - Valion Bio files to sell 29.41M shares of common stock, warrants - TheFly
- 21 days ago - Valion Bio Registration statement: Registration filing - Filings
- 21 days ago - Valion Bio Proxy statement: Proxy filing - Filings
- 24 days ago - Valion Bio reports continued development of Entolimod program - TheFly
- 24 days ago - Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion - PRNewsWire